TLX

Telix Pharmaceuticals Ltd ADR

• Seeking Alpha·05/18 22:43

  Telix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving Up

• PUBT·05/18 22:35

  Telix files Form 3 initial beneficial ownership statement for director David Gill

• PUBT·05/18 22:33

  Telix Pharmaceuticals director William Jellison files initial beneficial ownership statement

• PUBT·05/18 22:32

  Telix Pharmaceuticals files Form 3 as director Maria Rivas reports no holdings

• PUBT·05/18 21:26

  Telix completes IPAX-2 enrolment for TLX101-Tx in newly diagnosed glioblastoma

• Benzinga·05/18 21:10

  Telix Pharmaceuticals' IPAX-2 Study Of TLX101-Tx Completes Patient Enrolment; Maximum Dose Reached With No Dose-limiting Toxicities Observed; TLX101-Tx Is Also The Subject Of A Pivotal Trial, IPAX BrIGHT, Which Is Actively Dosing Patients With Recurrent Glioblastoma

• PUBT·05/18 21:01

  Telix completes enrolment in IPAX-2 Phase 1 glioblastoma trial of TLX101-Tx

• Reuters·05/18 21:00

  IPAX-2 STUDY OF TLX101-TX IN FIRST-LINE GLIOBLASTOMA COMPLETES ENROLMENT AND CONFIRMS DOSING

• Benzinga·05/18 10:28

  Why Is Regeneron Stock Sinking Monday?

• NASDAQ·05/15 11:57

  Telix, EDAP And Profound Partner To Explore PSMA-PET Imaging In Prostate Cancer Treatment

• Benzinga·05/15 10:33

  Telix Pharma Enters Into LOI To Pursue Collaborations With EDAP And Profound Medical To Explore Investigational Use Of Telix's PSMA-PET1 Imaging Agents Gozellix And Illuccix With Robotic HIFU, And Other Image-Guided Therapies To Treat Prostate Cancer

• Reuters·05/15 10:30

  TELIX ANNOUNCES COLLABORATIONS TO EXPLORE PSMA-PET IMAGING IN EMERGING PROSTATE CANCER TREATMENT APPROACHES

• PUBT·05/07 01:32

  Telix CEO Christian Behrenbruch acquires ordinary shares worth AUD 1.01 million

• PUBT·05/04 21:18

  Telix says analysis of Phase 3 ZIRCON data expands TLX250-Px kidney cancer detection

• Benzinga·05/04 21:03

  Telix Pharmaceuticals' TLX250-Px PET/CT Demonstrates High Predictive Accuracy Across All Renal Cancer Subtypes In Phase 3 ZIRCON Trial Analysis